JUST IN　•　MarketWatch.com - Top Stories

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

SHARE THIS STORYPLUS UNLOCKS FAVORITES READ LATER AND SOURCE CONTROL

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.

READ ORIGINAL REPORT ↗

THIS JUST HAPPENED PACKAGES THE WORLD INTO A FAST LIVE FEED SOURCE REPORTING STAYS ONE CLICK AWAY

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Akamai’s stock is surging. A $12 billion Anthropic deal reveals its powerful edge over cloud providers.

New York continues to fight prediction markets with a lawsuit against Polymarket

The S&P 500’s newest tech stock is now its best performer

P.E.I. woman who lost nearly $10K in bitcoin scam wants bank to reimburse her money

Africa's richest man helps fund $660m fuel pipeline between Ethiopia and Djibouti

Bring your co-founder, partner, or colleague and get 50% off a second TechCrunch Disrupt 2026 pass

New York defies Trump admin, asks court to shut down Polymarket gambling

West Bank herders use donkeys and trenches to move milk at night